Efficacy of Interleukin-1β Inhibitor on Dry Eye Disease in Patients with Degenerative Arthritis

References

• Lee WB, Mannis MJ. Historical Concepts of Ocular Surface Disease. Elsevier; 2013:3–10. doi:10.1016/b978-1-4557-2876-3.00001-8
   Google Scholar
• Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–283. doi:10.1016/j.jtos.2017.05.008
   PubMed Web of Science ®Google Scholar
• Lekhanont K, Rojanaporn D, Chuck RS, Vongthongsri A. Prevalence of dry eye in Bangkok, Thailand. Cornea. 2006;25(10):1162–1167. doi:10.1097/01.ico.0000244875.92879.1a
   PubMed Web of Science ®Google Scholar
• Ngamjit K, Suchaya G, Suphawadee E, Pamornsak T, Sutthichai J. Prevalence of dry eyes in elderly Thai population (the Romklao eye study). Asian Biomed. 2012;6(6):875–882. doi:10.5372/1905-7415.0606.134
   Web of Science ®Google Scholar
• Kelley J, Bohm ARD, Stephen C, Christopher E. Dry eye. In: Cornea. Elsevier; 2017:377–395. chap Chapter 33 Dry Eye.
   Google Scholar
• McDonald M, Patel DA, Keith MS, Snedecor SJ. Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review. Ocul Surf. 2016;14(2):144–167. doi:10.1016/j.jtos.2015.11.002
   PubMed Web of Science ®Google Scholar
• Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438–510. doi:10.1016/j.jtos.2017.05.011
   PubMed Web of Science ®Google Scholar
• Goldstein MH, Martel JR, Sall K, et al. Multicenter study of a novel topical interleukin-1 receptor inhibitor, isunakinra, in subjects with moderate to severe dry eye disease. Eye Contact Lens. 2017;43(5):287–296. doi:10.1097/icl.0000000000000276
   PubMed Web of Science ®Google Scholar
• Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7(1):33–42. doi:10.1038/nrrheum.2010.196
   PubMed Web of Science ®Google Scholar
• Spencer CM, Wilde MI. Diacerein. Drugs. 1997;53(1):98–106. doi:10.2165/00003495-199753010-00007
   PubMed Web of Science ®Google Scholar
• Thai Rheumatism Association. Guideline for the treatment of osteoarthritis of knee; 2010. Available from: https://thairheumatology.org/phocadownload/36/Guideline_003.pdf. Accessed September 15, 2023.
   Google Scholar
• Amparo F, Dastjerdi MH, Okanobo A, et al. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol. 2013;131(6):715–723. doi:10.1001/jamaophthalmol.2013.195
   PubMed Web of Science ®Google Scholar
• Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moça Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014;(2). doi:10.1002/14651858.CD005117.pub3
   PubMed Web of Science ®Google Scholar
• Pavelka K, Bruyère O, Cooper C, et al. Diacerein: benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. Drugs Aging. 2016;33(2):75–85. doi:10.1007/s40266-016-0347-4
   PubMed Web of Science ®Google Scholar
• Grosskreutz CL, Hockey H-U, Serra D, Dryja TP. Dry eye signs and symptoms persist during systemic neutralization of IL-1β by canakinumab or IL-17A by secukinumab. Cornea. 2015;34(12):1551–1556. doi:10.1097/ICO.0000000000000627
   PubMed Web of Science ®Google Scholar
• Lemp A. Report of the national eye institute/industry workshop on clinical trials in dry eyes. Eye Contact Lens. 1995;21(4):221–232.
   Google Scholar
• Bron AJ, Abelson MB, Ousler G, et al. Methodologies to diagnose and monitor dry eye disease: report of the diagnostic methodology subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):108–152. doi:10.1016/S1542-0124(12)70083-6
   PubMed Web of Science ®Google Scholar
• Keech A, Senchyna M, Jones L. Impact of time between collection and collection method on human tear fluid osmolarity. Curr Eye Res. 2013;38(4):428–436. doi:10.3109/02713683.2013.763987
   PubMed Web of Science ®Google Scholar
• Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15(3):539–574. doi:10.1016/j.jtos.2017.05.001
   PubMed Web of Science ®Google Scholar
• VanDerMeid KR, Su SP, Krenzer KL, Ward KW, Zhang JZ. A method to extract cytokines and matrix metalloproteinases from Schirmer strips and analyze using Luminex. Mol Vis. 2011;17:1056–1063.
   PubMed Web of Science ®Google Scholar
• Schiffman RM, Christianson M, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000;118(5):615–621. doi:10.1001/archopht.118.5.615
   PubMedGoogle Scholar
• Park Y, Song JS, Choi CY, Yoon KC, Lee HK, Kim HS. A randomized multicenter study comparing 0.1%, 0.15%, and 0.3% sodium hyaluronate with 0.05% cyclosporine in the treatment of dry eye. J Ocul Pharmacol Ther. 2017;33(2):66–72. doi:10.1089/jop.2016.0086
   PubMed Web of Science ®Google Scholar
• Kheirkhah A, Di Zazzo A, Satitpitakul V, Fernandez M, Magilavy D, Dana R. A pilot randomized trial on safety and efficacy of a novel topical combined inhibitor of Janus Kinase 1/3 and spleen tyrosine kinase for GVHD-associated ocular surface disease. Cornea. 2017;36(7):799–804. doi:10.1097/ico.0000000000001206
   PubMed Web of Science ®Google Scholar
• Bartlett JD, Keith MS, Sudharshan L, Snedecor SJ. Associations between signs and symptoms of dry eye disease: a systematic review. Clin Ophthalmol. 2015;9:1719–1730. doi:10.2147/opth.S89700
   PubMed Web of Science ®Google Scholar
• Kyei S, Dzasimatu SK, Asiedu K, Ayerakwah PA. Association between dry eye symptoms and signs. J Curr Ophthalmol. 2018;30(4):321–325. doi:10.1016/j.joco.2018.05.002
   PubMed Web of Science ®Google Scholar
• Onwubiko SN, Eze BI, Udeh NN, Onwasigwe EN, Umeh RE. Dry eye disease: concordance between the diagnostic tests in African eyes. Eye Contact Lens. 2016;42(6):395–400. doi:10.1097/icl.0000000000000218
   PubMed Web of Science ®Google Scholar
• Unlu C, Guney E, Akcay BI, Akcali G, Erdogan G, Bayramlar H. Comparison of ocular-surface disease index questionnaire, tearfilm break-up time, and Schirmer tests for the evaluation of the tearfilm in computer users with and without dry-eye symptomatology. Clin Ophthalmol. 2012;6:1303–1306. doi:10.2147/opth.S33588
   PubMedGoogle Scholar
• Che Arif FA, Hilmi MR, Kamal MK, Ithnin MH. Comparison of immediate effects on usage of dual polymer artificial tears on changes in tear film characteristics. Malaysian J Med Health Sci. 2021;17(3):252–258.
   Google Scholar
• Che Arif FA, Hilmi MR, Kamal KM. A prospective contralateral eye comparison of the tolerability of two artificial tears with different physical properties in patients with dry eye disease. Med Hypothesis Discov Innov Optom. 2023;4(1):1–6. doi:10.51329/mehdioptometry167
   Google Scholar
• Wan KH, Chen LJ, Young AL. Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysis. Ocul Surf. 2015;13(3):213–225. doi:10.1016/j.jtos.2014.12.006
   PubMed Web of Science ®Google Scholar
• Rao SN. Topical cyclosporine 0.05% for the prevention of dry eye disease progression. J Ocul Pharmacol Ther. 2010;26(2):157–164. doi:10.1089/jop.2009.0091
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Netea MG. The interleukin-1 family. In: Fundamental Immunology. 7th ed. Lippincott Williams & Wilkins; 2013.
   Google Scholar
• Zhao H, Li Q, Ye M, Yu J. Tear luminex analysis in dry eye patients. Med Sci Monit. 2018;24:7595–7602. doi:10.12659/msm.912010
   PubMed Web of Science ®Google Scholar
• Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42(10):2283–2292.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8–27. doi:10.1111/imr.12621
   PubMed Web of Science ®Google Scholar
• Moldovan F, Pelletier JP, Jolicoeur FC, Cloutier JM, Martel-Pelletier J. Diacerhein and rhein reduce the ICE-induced IL-1beta and IL-18 activation in human osteoarthritic cartilage. Osteoarthritis Cartilage. 2000;8(3):186–196. doi:10.1053/joca.1999.0289
   PubMed Web of Science ®Google Scholar
• Martel-Pelletier J, Mineau F, Jolicoeur FC, Cloutier JM, Pelletier JP. In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol. 1998;25(4):753–762.
   PubMed Web of Science ®Google Scholar
• Yaron M, Shirazi I, Yaron I. Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthritis Cartilage. 1999;7(3):272–280. doi:10.1053/joca.1998.0201
   PubMed Web of Science ®Google Scholar
• Chiu JW, Binte Hanafi Z, Chew LCY, Mei Y, Liu H. IL-1α processing, signaling and its role in cancer progression. Cells. 2021;10(1):92. doi:10.3390/cells10010092
   PubMed Web of Science ®Google Scholar
• Uchino E, Sonoda S, Kinukawa N, Sakamoto T. Alteration pattern of tear cytokines during the course of a day: diurnal rhythm analyzed by multicytokine assay. Cytokine. 2006;33(1):36–40. doi:10.1016/j.cyto.2005.11.013
   PubMed Web of Science ®Google Scholar
• Benito MJ, González-García MJ, Tesón M, et al. Intra- and inter-day variation of cytokines and chemokines in tears of healthy subjects. Exp Eye Res. 2014;120:43–49. doi:10.1016/j.exer.2013.12.017
   PubMed Web of Science ®Google Scholar
• Luo L, Li DQ, Corrales RM, Pflugfelder SC. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens. 2005;31(5):186–193. doi:10.1097/01.icl.0000162759.79740.46
   PubMedGoogle Scholar
• Chen H, Chen H, Liang L, et al. Evaluation of tear protein markers in dry eye disease with different lymphotoxin-alpha expression levels. Am J Ophthalmol. 2020;217:198–211. doi:10.1016/j.ajo.2020.03.013
   PubMed Web of Science ®Google Scholar
• Kimura K, Teranishi S, Nishida T. Interleukin-1beta-induced disruption of barrier function in cultured human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2009;50(2):597–603. doi:10.1167/iovs.08-2606
   PubMed Web of Science ®Google Scholar